Compare Ross Stores, Inc. (ROST) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Tango Therapeutics Inc. — how do they compare? Ross Stores, Inc. trades at $230.5 (market cap $72.09B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Ross Stores, Inc. is far larger — about 19.2× Tango Therapeutics Inc.'s market cap, and Ross Stores, Inc. pays a 0.79% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and Tango Therapeutics Inc. for 0 Days on average.
| ROST | TNGX | |
|---|---|---|
Market Cap | $72.09B | $3.75B |
Volume | 1,593,708 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $32.90 |
52-Week Low | $155.21 | $7.50 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $72.55B | $2.77B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $230.57, up 2.09% today, showing strong momentum with three consecutive earnings beats. The stock faces technical headwinds with a bearish signal but maintains robust fundamentals including 42.63% ROE and 10.85% net margins. Recent news highlights store expansion initiatives and strong closeout supply positioning the company to capture value-conscious consumer demand.
ROST presents a compelling investment case with analyst consensus target of $274.14 (19% upside) and strong institutional support. However, near-term technical weakness and competitive pressures in discount retail require monitoring. The company's consistent earnings outperformance and expanding margins support long-term growth prospects despite current market volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
